BioSpace News Archive

NDA Resubmission to the FDA Expected to Occur in the First Quarter of 2020

ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first patient has been treated in the company’s First-in-Human trial with its lead drug candidate ONL1204

Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced David Adair, M.D. will join the Mayfield Pharmaceuticals Board of Directors

Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2019 American Society for Dermatologic Surgery Annual Meeting in Chicago, IL October 24-27 2019.

ImpediMed Limited announces the kickoff of the company’s new, comprehensive Lymphedema Prevention Program with the goal of ending cancer-related lymphedema.

Rigel Pharmaceuticals, Inc. provided a business update that will be discussed in more detail on the company’s investor and analyst call

TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) (“TerrAscend” or “the Company”), the first and only global cannabis company licensed for sales in Canada, the US, and the EU, announced today that it has formed a strategic partnership with Kindred Partners Inc.

Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced a collaboration with CYTOO aimed at informing the development of new AXA Candidates by leveraging CYTOO’s MyoScreenTM muscle-on-a-plate platform.

Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Wednesday, October 30, 2019 at 5:00 p.m. Eastern Time to discuss financial results for the third quarter of 2019 and provide a corporate update.

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, reported financial results for the quarter ended September 30, 2019.